HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report) was the target of a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 446 shares, an increase of 792.0% from the July 15th total of 50 shares. Based on an average daily trading volume, of 1,133 shares, the short-interest ratio is currently 0.4 days.
HLS Therapeutics Stock Performance
Shares of OTCMKTS HLTRF opened at $2.75 on Wednesday. HLS Therapeutics has a 1 year low of $2.75 and a 1 year high of $4.02. The firm’s 50 day moving average price is $3.06 and its 200 day moving average price is $3.22.
About HLS Therapeutics
HLS Therapeutics is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription products for niche therapeutic markets. Headquartered in Mississauga, Ontario, the company builds its portfolio through strategic licensing agreements and in-house development, with an emphasis on therapies that address unmet needs in neurology and rare disorders.
The company’s marketed offering includes treatments for neurological conditions, most notably primary periodic paralysis, for which it commercializes dichlorphenamide (Keveyis) in North America.
Featured Stories
- Five stocks we like better than HLS Therapeutics
- Hims & Hers’ Revenue Beat Came With a Profitability Problem
- A Westinghouse IPO Could Reset the Nuclear Stock Conversation
- Fastly’s Q2 Rally Shows Investors Are Buying the Edge AI Turnaround
- Paramount’s 30-Film Promise Puts AMC Back in the Box Office Conversation
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
